Clinical Trial

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2023 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-04-10.
Trial Details
NCT Number NCT05331105
Lead Sponsor Shanghai Kechow Pharma, Inc.
Conditions Neurofibromatosis 1, Plexiform Neurofibromas
Enrollment 70 participants
Start Date 2021-10-18
Primary Completion 2025-10-30 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-31